Berakhot Posted - 16 hours ago

$MDT $MDAI

HeyDuggee Posted - 18 hours ago

$MDAI $MDT Breakthrough technology DYOR

tradingtwenty Posted - 2 days ago

$MDT has trended 42 times in the past 24 hours (based on 5 minute intervals). Latest press release on May 17, 2024 04:31 PM: Medtronic Affera™ Mapping and Ablation System with Sphere-9™ Catheter achieves endpoints for safety and efficacy... Link: https://tradingtwenty.com/news/477944/medtronic-affera-mapping-and-ablation-system-with-sphere-9-catheter-achieves-endpoints-for-safety-and-efficacy-providing-promising-evidence-for-the-future-of-atrial-fibrillation-treatment

DonCorleone77 Posted - 2 days ago

$MDT Medtronic reports 'positive' results from SPHERE Per-AF study Medtronic announced positive results demonstrating excellent safety and efficacy of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one pulsed field and radiofrequency ablation and high density mapping catheter for the treatment of persistent atrial fibrillation. The SPHERE Per-AF study, a U.S. FDA Investigational Device Exemption pivotal trial, compared Sphere-9 to the conventional Thermocool SmartTouch SF radiofrequency ablation catheter with the Carto 3 System. Findings were presented as late-breaking clinical data at the Heart Rhythm Society 2024 Annual Meeting and simultaneously published in Nature Medicine.

Stock_Titan Posted - 3 days ago

$MDT Medtronic Affera™ Mapping and Ablation System with Sphere-9™ Catheter achieves endpoints for safety and efficacy, providing promising evidence for the future of atrial fibrillation treatment https://www.stocktitan.net/news/MDT/medtronic-affera-mapping-and-ablation-system-with-sphere-9-catheter-vngeg84y02x9.html

DonCorleone77 Posted - 3 days ago

$MDT Medtronic says OmniaSecure met primary safety, effectiveness endpoints Medtronic announced that its investigational OmniaSecure defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals, in the global Lead Evaluation for Defibrillation and Reliability Pivotal Trial. Late breaking results were presented at Heart Rhythm 2024 and simultaneously published in the journal Heart Rhythm. Worldwide, the OmniaSecure defibrillation lead is investigational and not yet approved for sale or distribution. Implantable cardioverter defibrillators are the gold standard for preventing sudden cardiac death. Yet transvenous defibrillator leads, which are thin wires connected to the ICD and threaded through the veins into the heart muscle, remain the weakest point of the system, given the harsh environment inside the human body where the lead must remain attached and yet flex with millions of heart contractions over a patient's lifetime. Existing defibrillation leads have a large diameter, which can contribute to venous occlusion or tricuspid valve complications. For patients where an extravascular defibrillator may not be appropriate, Medtronic engineers designed the OmniaSecure defibrillation lead based on the Medtronic SelectSecure Model 3830 pacing lead, which has offered safe and effective treatment to patients for more than 20 years. By beginning with this highly reliable pacing lead and building a larger lead suitable for defibrillation therapy, the Medtronic OmniaSecure lead is the world's smallest transvenous defibrillation lead. Defibrillation testing conducted at device implantation in 119 patients was successful in 97.5% of cases. The study exceeded the prespecified efficacy goal of 88%. At six months, 97.1% of 657 patients with an implant attempt were free from lead-related major complications such as hospitalization, lead fracture, system revision, or death. The study exceeded the prespecified safety performance goal of 90%. There were no lead-related major complications observed between six and 12 months. The LEADR Pivotal trial is a prospective, multicenter, single-arm, non-randomized, global clinical study that assessed the safety and effectiveness of the Medtronic OmniaSecure defibrillation lead when placed at traditional locations in the right ventricle to achieve defibrillation, sensing, pacing and cardioversion in patients at risk of sudden cardiac death. The study enrolled 675 patients at 45 sites in 17 countries in North America, Europe, Asia, and Australia. The lead demonstrated reliable performance with zero study lead fractures through an average follow up of 12.7+/-4.8 months. Medtronic developed and validated an in-vitro model that accurately predicts lead reliability out to 10 years,2 and then applied that model within the study to predict a fracture-free survival of 99.9% at two years for the investigational OmniaSecure lead. The lead also demonstrated a 97.9% implant success rate, and stable electricals through 12 months. Nearly 12% of patients in the study received appropriate therapy for dangerously fast ventricular arrhythmias by 14.0+/-5.0 months. ATP terminated 74.9% of episodes, preventing a shock in 49 patients. Medtronic plans to present additional reliability model results from the LEADR study in the coming months.

Longaeva_Capital Posted - 4 days ago

$MDT looks like an inverse head and shoulders setting up into earnings.

ApexSeidon Posted - 5 days ago

$MDT 86C 5/24exp $333k .97 Avg

jheerdink Posted - 5 days ago

$MODD "Welcome to Diabetes Made Simpler" The MODD1 is designed for those who want an insulin pump that removes complicated technology and allows for a smooth transition from manual injections. Designed with simplicity in mind, it facilitates data sharing with care teams. SEE HOW IT WORKS https://www.modular-medical.com/modd1 obviously related to $PODD $MDT businesses

DonCorleone77 Posted - 6 days ago

$PODD $MDT Here is more info. I have no position: Blue Orca goes short Insulet, sees 'immediate' 15% share drop Blue Orca Capital announced a short position in shares of Insulet (PODD). The firm anticipates an "immediate" 15%-plus drop in shares, saying Insulet will reverse the gains it made upon the granting of the injunction "and as investors awaken to the restoration of an imminent competitive threat to Insulet's flagship product monopoly." The appellate court decision restores EOFlow's business, clears the path for Medtronic (MDT) to acquire EOFlow, and "shatters" Insulet's U.S. monopoly on tubeless automated insulin delivery systems, Blue Orca contends in a short report posted on its website. "It is highly misleading for Insulet to conceal from investors that the appellate court killed the very injunction which protected its competitive moat and was so material to its stock that, when the injunction was granted, its market capitalization gained $1.8 billion," according to the firm.

SimplyP Posted - 1 week ago

$MDT daily. iHS setup? neckline 88.76, target 106.90 on neckline break. if neckline rejected, back to 84ish, and then up and over.

RNAlivesmatter Posted - 1 week ago

$MDT not making a move

Stock_Titan Posted - 1 week ago

$MDT Medtronic to announce financial results for its fourth quarter and full fiscal year 2024 https://www.stocktitan.net/news/MDT/medtronic-to-announce-financial-results-for-its-fourth-quarter-and-upi6h70amdvw.html

Ro_Patel Posted - 2 weeks ago

Goldman Sachs expects stock dividends to grow by more than +6% this year. Prior-year EPS growth is the most predictive variable for DPS (dividend per share) growth Goldman analysts list the constituents of their dividend yield & growth basket, with data as of April 18 $CVX $BX $MDT $CSCO $QCOM

muldoon92 Posted - 2 weeks ago

@ocled which company would you gather? $MDT ?

Shortslie Posted - 2 weeks ago

$BSGM move shares from Margin to Cash account-critical into next week’s mtg Pls support great new CEO into next weeks mtg with only 9 mill shares O/S this WILL help reduce shares to borrow/short. Read detail on why this helps here: https://www.reddit.com/r/investing_discussion/comments/1c2gsjl/help_reduce_bsgm_shares_available_to/ $ABT $JNJ $MDT $BSX

Stock_Titan Posted - 2 weeks ago

$MDT Medtronic: 'Pivotal Moment' in Women's Heart Health https://www.stocktitan.net/news/MDT/medtronic-pivotal-moment-in-women-s-heart-bg6rhuswm1gd.html

John_Wick1234 Posted - 04/30/24

$MDT Nice Double Bottom

Ravenskys1 Posted - 04/29/24

$MDT $BSX https://www.linkedin.com/posts/paulverrastro_amazing-boston-scientifics-market-cap-is-activity-7189992619987415040-5SVA?utm_source=share&utm_medium=member_ios

Fundays Posted - 04/26/24

$MDT sideways or down for 5 years now. How about giving the shareholders a raise via a significant bump in dividend

StockRedBaron Posted - 04/26/24

$MDT What AMAZING NEWS!!! https://quantisnow.com/insight/5435752

Stock_Titan Posted - 04/26/24

$MDT Medtronic receives FDA approval for Inceptiv™ closed-loop spinal cord stimulator https://www.stocktitan.net/news/MDT/medtronic-receives-fda-approval-for-inceptiv-closed-loop-spinal-cord-gb3z78uvyj8u.html

TraderJoeGettinDough Posted - 04/25/24

$MDT trading below 50 and 200 day, trending down. I could see this touching 75 or 70 unfortunately. Would be good entry points for long position. I will continue accumulating

LMDXWILLBOOM Posted - 04/24/24

$LMDX The fact that Roche just sold that compound to lonza for 1.2B prior to a positive earnings report can definitely heat up this deal. Lumiradx can integrate with Cobas & Navify making Roche the ultimate solution for PoC. $mdt ain't got shiet.

DefenseMania Posted - 04/24/24

$LLY $ABT $MDT $NVDA

PremiumHarvester Posted - 04/23/24

$MDT Heading to $83 soon.

TraderJoeGettinDough Posted - 04/23/24

$MDT once rates are cut, this could shoot back up. Once people can’t get guaranteed 5%, this 3.4% dividend aristocrat (almost king!) will be next in line.

LMDXWILLBOOM Posted - 04/23/24

$LMDX first there was the NES then there was SNES then N64 sounds like $mdt & Alere. Time to upgrade these obsolete cows.

LMDXWILLBOOM Posted - 04/23/24

$LMDX $mdt would not exist if it wasn't for RonCo! The ultimate chess players 👌 I can wait.

HaterAdeTime Posted - 04/23/24

$MDT party time